Engineered E. coli Producing Microcin H47 for Salmonella Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antibiotic-resistant bacteria, such as those from the Enterobacteriaceae family, poses a significant challenge in healthcare due to increased morbidity, mortality, and healthcare costs, necessitating novel therapeutics that can selectively target and inhibit pathogenic bacteria without promoting resistance.
Innovation Solution
Genetically engineered Escherichia coli strains are developed to produce microcin peptides, such as Microcin H47, which are induced by environmental signals like intestinal inflammation, allowing for targeted antimicrobial activity against pathogens like Salmonella Typhimurium, using plasmid-based systems that control peptide production in response to tetrathionate or L-rhamnose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then infection rates are reduced, but antibiotic resistance emerges and increases
Solution Approach 1:
The patent uses engineered E. coli as a living intermediary that produces microcin H47 peptides to indirectly kill pathogenic bacteria. Instead of directly administering antibiotics that select for resistance, the engineered commensal bacteria serve as a mediator that delivers antimicrobial activity through peptide production, reducing direct antibiotic pressure and resistance selection.
Solution Approach 2:
The engineered E. coli strains autonomously produce microcin H47 peptides in response to environmental signals like tetrathionate or L-rhamnose that indicate inflammation or pathogen presence. The system self-regulates antimicrobial production based on physiological conditions, eliminating the need for external antibiotic administration and reducing resistance development.
2Adaptability or versatility
If broad-spectrum antibiotics are administered, then multiple bacterial infections are treated, but beneficial microbiota are eliminated causing dysbiosis
Solution Approach 1:
The patent employs narrow-spectrum microcin H47 peptides that specifically target Gram-negative pathogens while sparing other bacteria. The engineered E. coli produces peptides with localized specificity rather than broad-spectrum activity, preserving beneficial microbiota composition while treating infections. Different engineered strains can be used for different pathogens, providing targeted therapy.
Solution Approach 2:
The engineered E. coli autonomously produces antimicrobial peptides only when environmental signals indicate pathogen presence or inflammation, rather than continuously producing antibiotics that would disrupt microbiota. This conditional, self-regulated production maintains microbiota stability while providing infection coverage when needed.
3Reliability
If continuous production of antimicrobial peptides is maintained, then pathogen inhibition is effective, but metabolic burden increases and host cells may be affected
Solution Approach 1:
The patent implements periodic, signal-induced production of microcin H47 peptides rather than continuous production. The controllable promoters activate peptide synthesis only in response to specific environmental signals like tetrathionate or L-rhamnose, creating pulsed antimicrobial activity that reduces metabolic burden while maintaining effective pathogen inhibition when needed.
Solution Approach 2:
The patent uses controllable promoters that change their activity state based on environmental parameters (presence of inducing agents). The promoter switches between active and inactive states, dynamically adjusting peptide production levels to match physiological conditions, thereby optimizing the balance between pathogen inhibition and metabolic energy consumption.
4Object-affected harmful factors
If genetically engineered microorganisms are used for targeted therapy, then selective antimicrobial activity is achieved, but regulatory control and safety monitoring become more complex
Solution Approach 1:
The patent uses naturally occurring environmental molecules (tetrathionate, L-rhamnose) as intermediary signaling agents that trigger peptide production. These endogenous metabolites serve as simple, naturally-occurring inducers that avoid the need for complex synthetic regulatory systems, reducing overall system complexity while maintaining selective targeting capability.
Solution Approach 2:
The patent employs universal, well-characterized genetic tools and promoters (e.g., pBAD, Pttr) that can be controlled with standard inducing agents. These multi-functional genetic circuits can respond to various environmental signals and are broadly applicable across different engineered strains, simplifying regulatory control compared to custom-designed complex systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The genetically engineered E. coli effectively inhibits the growth of Salmonella Typhimurium in both static agar inhibition assays and ecological competition experiments, demonstrating a significant fitness advantage and potential for microbiome correction during disease states.
Implementation Method 1
the controllable promoter controls a level of expression of the one or more microcin genes, thereby controlling the amount of microcin produced by the genetically engineered microorganism
Implementation Method 2
production of small antimicrobial peptides such as microcin, that are capable of inhibiting the organism responsible for the inflammation
Data Source
AI summary
This disclosure relates to genetically engineered microorganisms for treating or reducing the risk of bacterial infections or dysbiosis, and further discloses methods of making and using such microorganisms.